Brexpiprazole Indications and Evidence for Mood Outbursts
Brexpiprazole is not an FDA-approved treatment for “mood outbursts” in general. [1] Brexpiprazole is FDA-approved for adjunctive treatment of major depressive disorder in adults, treatment of schizophrenia, and treatment of agitation associated with dementia due to Alzheimer’s disease. [1]
FDA-Approved Indications Relevant to Acute Behavioral Symptoms
Brexpiprazole is indicated for agitation associated with dementia due to Alzheimer’s disease. [1] Brexpiprazole is not indicated for dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease. [1] Brexpiprazole is not indicated as an as-needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease. [1]
Medication Selection Algorithm for “Outbursts”
- Evaluate for a diagnosis matching an FDA indication (major depressive disorder, schizophrenia, or agitation associated with dementia due to Alzheimer’s disease). [1]
- If the symptom pattern is not agitation due to dementia from Alzheimer’s disease, brexpiprazole use is not supported by FDA labeling for that specific presentation. [1]
Key Evidence Base for Agitation in Alzheimer Dementia
Two 12-week, randomized, double-blind, placebo-controlled fixed-dose trials evaluated brexpiprazole for agitation associated with dementia due to Alzheimer’s disease. [1] A randomized clinical trial reported efficacy of brexpiprazole for treatment of agitation in Alzheimer dementia. [2]
Monotherapy Versus Combination Therapy
For major depressive disorder, brexpiprazole is indicated only as adjunctive treatment to antidepressant therapy. [1] For agitation associated with dementia due to Alzheimer’s disease, brexpiprazole is studied as an oral once-daily treatment regimen, not as an as-needed (“prn”) medication. [1]
Initiation Thresholds and Practical Limitations
Brexpiprazole labeling specifies that it is not an as-needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease. [1] Dosing for agitation associated with dementia due to Alzheimer’s disease is specified in the product labeling rather than being used for immediate breakthrough “outbursts.” [1]
Common Pitfalls to Avoid
Using brexpiprazole for dementia-related psychosis without agitation is inconsistent with FDA labeling. [1] Using brexpiprazole as a rapid-response “prn” medication for agitation associated with dementia due to Alzheimer’s disease is inconsistent with FDA labeling. [1]
Safety Considerations in Dementia-Related Behavioral Symptoms
Brexpiprazole carries an FDA boxed warning for increased mortality in elderly patients with dementia-related psychosis treated with antipsychotic drugs. [1] Brexpiprazole labeling emphasizes the limitation for dementia-related psychosis without agitation associated with dementia due to Alzheimer’s disease. [1]